Journal of Clinical Endocrinology & Metabolism, Vol 74, 75-83, Copyright © 1992 by Endocrine Society

ARTICLES

A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men

S Bhasin, RS Swerdloff, B Steiner, MA Peterson, T Meridores, M Galmirini, MR Pandian, R Goldberg and N Berman
Harbor-University of California-Los Angeles Medical Center, Torrance 90509.

Limitations of presently available testosterone esters (enanthate and cypionate) include the fluctuating serum testosterone levels and the need for relatively frequent injections (every 10-21 days). These limitations of testosterone esters have prompted the development of more physiological and longer acting systems for androgen delivery. This paper reports pharmacokinetic and pharmacodynamic data with a second generation long-acting testosterone microcapsule formulation in hypogonadal men. This was a single dose, open label, nonrandomized study. Ten hypogonadal men with primary (n = 6) or secondary (n = 4) hypogonadism, otherwise in good health, received 630 mg microencapsulated testosterone in dextran solution (IM) on day 1. Serum total and free testosterone; LH; FSH; dihydrotesterone; estradiol; sex hormone-binding globulin; total cholesterol; high, low, and very low density lipoprotein cholesterol; triglycerides; and apoprotein-AII and - B were measured on multiple occasions during the 2-week control period and the 16-week treatment period. In addition, on days 0, 1, 28, 56, and 84, subjects were hospitalized for detailed hormone analyses over the 24-h period. Serum total and free testosterone levels rose quickly into the midnormal range and stayed uniformly in the eugonadal range for about 70-77 days, after which serum testosterone levels declined gradually into the hypogonadal range. Testosterone release from the microcapsule formulation over the first 10 weeks approximated zero order kinetics. Serum dihydrotestosterone levels rose into the normal range, and testosterone to dihydrotestosterone ratios remained in the physiological range. Serum estradiol levels rose and stayed in the midnormal male range. Serum sex hormone-binding globulin levels decreased significantly during treatment. Serum LH and FSH levels also significantly decreased in the six hypergonadotropic men. Total cholesterol low and very low density lipoprotein cholesterol and triglyceride levels did not change, but plasma high density lipoprotein cholesterol levels decreased significantly during treatment. These data indicate that testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for about 10 weeks. The long duration and zero order kinetics make it an attractive alternative to existing methods of androgen replacement.

This article has been cited by other articles:

				K. S. Fritz, A. J.S. McKean, J. C. Nelson, and R. B. Wilcox Analog-Based Free Testosterone Test Results Linked to Total Testosterone Concentrations, Not Free Testosterone Concentrations Clin. Chem., March 1, 2008; 54(3): 512 - 516. [Abstract] [Full Text] [PDF]

				M. Wald, R. B. Meacham, L. S. Ross, and C. S. Niederberger Testosterone Replacement Therapy for Older Men J Androl, March 1, 2006; 27(2): 126 - 132. [Full Text] [PDF]

				R. Casaburi, S. Bhasin, L. Cosentino, J. Porszasz, A. Somfay, M. I. Lewis, M. Fournier, and T. W. Storer Effects of Testosterone and Resistance Training in Men with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 870 - 878. [Abstract] [Full Text] [PDF]

				L. Turner, A. J. Conway, M. Jimenez, P. Y. Liu, E. Forbes, R. I. McLachlan, and D. J. Handelsman Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4659 - 4667. [Abstract] [Full Text] [PDF]

				F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF]

				A. Vermeulen Androgen Replacement Therapy in the Aging Male--A Critical Evaluation J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2380 - 2390. [Full Text] [PDF]

				A. S. Dobs, A. W. Meikle, S. Arver, S. W. Sanders, K. E. Caramelli, and N. A. Mazer Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3469 - 3478. [Abstract] [Full Text] [PDF]

				R. A. Anderson, C. W. Martin, A. W. C. Kung, D. Everington, T. C. Pun, K. C. B. Tan, J. Bancroft, K. Sundaram, A. J. Moo-Young, and D. T. Baird 7{alpha}-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3556 - 3562. [Abstract] [Full Text] [PDF]

				D. E. Cummings, N. Kumar, C. W. Bardin, K. Sundaram, and W. J. Bremner Prostate-Sparing Effects in Primates of the Potent Androgen 7{alpha}-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4212 - 4219. [Abstract] [Full Text]

				R. S. Swerdloff, C. J. Bagatell, C. Wang, B. D. Anawalt, N. Berman, B. Steiner, and W. J. Bremner Suppression of Spermatogenesis in Man Induced by Nal-Glu Gonadotropin Releasing Hormone Antagonist and Testosterone Enanthate (TE) Is Maintained by TE Alone J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3527 - 3533. [Abstract] [Full Text]

				E. Diamanti-Kandarakis, A. Mitrakou, S. Raptis, G. Tolis, and A. J. Duleba The Effect of a Pure Antiandrogen Receptor Blocker, Flutamide, on the Lipid Profile in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2699 - 2705. [Abstract] [Full Text]

				A. S. Dobs, D. R. Hoover, M.-C. Chen, and R. Allen Pharmacokinetic Characteristics, Efficacy, and Safety of Buccal Testosterone in Hypogonadal Males: A Pilot Study J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 33 - 39. [Abstract] [Full Text]

				S. Bhasin, T. W. Storer, N. Berman, K. E. Yarasheski, B. Clevenger, J. Phillips, W. P. Lee, T. J. Bunnell, and R. Casaburi Testosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 407 - 413. [Abstract] [Full Text] [PDF]

				S. Bhasin, T. W. Storer, N. Berman, C. Callegari, B. Clevenger, J. Phillips, T. J. Bunnell, R. Tricker, A. Shirazi, and R. Casaburi The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men N. Engl. J. Med., July 4, 1996; 335(1): 1 - 7. [Abstract] [Full Text] [PDF]

				C. J. Bagatell and W. J. Bremner Androgens in Men -- Uses and Abuses N. Engl. J. Med., March 14, 1996; 334(11): 707 - 715. [Full Text] [PDF]